{
  "docId": "019dd923-622c-750b-8b99-9ee2a1e788fb",
  "docSlug": "1233d0b05ad9",
  "documentTitle": "PROCEPT BioRobotics Corporation (PRCT)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-01-16 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 10,
  "pageCount": 100,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "This slide serves as a continuation of the executive summary, focusing on financial skepticism and valuation disconnect.",
  "elementsJson": [
    "headline_text",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-9ee2a1e788fb/10",
  "deckHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb#slide-10",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Based on our belief that Procept is likely to face growth challenges, we believe the Company should trade at 5x to 9x 2025E revenue, implying a price target range of $29 to $54 per share, or approximately 30% to 60% downside from current levels.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-ee35-7258-b4d7-e5f7f962ea31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "revenue multiple: 14x",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-ee35-7258-b4d7-e8cbaab8a8f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.415,
        "w": 0.956,
        "x": 0.022,
        "y": 0.545
      },
      "kind": "paragraph",
      "text": "We believe Procept's valuation is absurd. Procept trades at a $4.7 billion market cap and a 14x 2025E revenue multiple despite being an unprofitable, niche, highly disruptable, single-product company with structural growth barriers. Procept's valuation disconnect is particularly pronounced when compared to peers, which average just 5.5x revenue. We believe Procept is benefitting from its association with the \"robotic surgery\" and \"AI\" themes, even though both are questionable descriptors of the Company's business or capabilities. In fact, when we compare Procept to robotic surgery pioneer Intuitive Surgical (ISRG), the valuation north star for Procept bulls given its sector leading multiple, we find that any comparisons between the two are highly inappropriate. We also highlight that many of the bull case arguments of some sell-side analyst cheerleaders stand in direct conflict with Company statements and our research. In order to drive home the irrationality of Procept's valuation, we do an illustrative analysis of the Company's aggregate revenue and EBITDA opportunity over the next ten years. Despite making highly optimistic assumptions, such as 100% high volume and 50% low volume hospital penetration and 75% Aquablation share of resective procedures, we estimate that Procept's TOTAL 10-year revenue opportunity is just $1.9 billion, or less than half its current enterprise value. We believe Procept bulls must suspend all disbelief and be confident of perfect execution to come anywhere close to meeting Street estimates, which, as is, still call for declining revenue growth rates, the death knell for super-premium multiples. Based on our belief that Procept is likely to face growth challenges, we believe the Company should trade at 5x to 9x 2025E revenue, implying a price target range of $29 to $54 per share, or approximately 30% to 60% downside from current levels.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "823aa684-0f21-4dc6-b8e7-48e4bac3edb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.355,
        "w": 0.956,
        "x": 0.022,
        "y": 0.185
      },
      "kind": "paragraph",
      "text": "Beyond the Company's questionable revenue growth potential, we are also skeptical of consensus expectations for improved operating leverage. Street estimates call for over 500 bps of gross margin expansion over the next two years. However, we find that none of Procept's peers were able to achieve such levels of gross margin expansion when they grew from approximately $200 to $400 million of revenue. Additionally, we believe that Procept handpieces contain little differentiated or unique content and suspect that they are ripe for price compression over the coming years. Moreover, given the Company's history of frequent reclassifications and changing definitions, we have concerns about Procept's inventory, cost of goods sold, and thus gross margin accounting, particularly since the Company's lead audit partners have minimal to no experience with revenue-generating companies. We also lack confidence that Procept will be able to reduce the cost burden of its utilization reps, who will only become less efficient as the Company penetrates smaller, more geographically dispersed hospitals, and we note that the Company is still spending $700,000 in non-GAAP sales and marketing expense (excluding stock-based compensation) to sell each ~$425,000 ASP system. Thus, we believe Procept may be structurally unprofitable.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4b2171a-b42a-449a-96c8-773b242f4ac6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.375,
        "x": 0.313,
        "y": 0.055
      },
      "kind": "title",
      "text": "Executive Summary, Continued",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2770323c-17a2-4237-875b-05bcf8013a25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis: Activist defense (for management)",
      "slug": "activist-defense",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "d9dd9ec2-84b1-4994-ae80-d570e4a69431",
      "evidence": "We believe Procept's valuation is absurd. Procept trades at a $4.7 billion market cap and a 14x 2025E revenue multiple despite being an unprofitable, niche, highly disruptable, single-product company",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}